Trius Therapeutics (TSRX) is a recent stock that our investment group has been buying. Our last buy was Sarepta Therapeutics (NASDAQ:SRPT) which is up 10% in the last 2 weeks. Biggest winners include Map Pharmaceuticals …
For the professionals that use FactSet, this is what the coding can look like: Trius Terapeutics (NASDAQ:TSRX). Last quarter the company had an EPS of -0.38 compared to -0.22 from the year before. In the past 3 months, the stock is up …
Stock
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly ... Article printed from InvestorPlace Media, http://investorplace.com/2014/02/7-biotechnology-stocks-to-sell-now-siga-tsrx-nsph-2/.
Trius Therapeutics, Inc. (NASDAQ: TSRX) filed a registration statement with the SEC for an initial public offering of its common stock. The proposed maximum aggregate offering price is $86.25 million. The company plans to list on the …
News about Trius Therapeutics, Inc. SAN DIEGO - January 18, 2013 (Investorideas.com Newswire) Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced the pricing of an underwritten public offering of 6,300,000 shares of its common stock
Trius Therapeutics, Inc. (TSRX): Total insider Purchases of $54.4 million This ... See the details of these transactions and stock returns since the IPO at Insider Monkey. 2. Everest Re Group Ltd. (RE): Total Insider Purchases of $64.7 million …
Like Crazy
Shares of Trius Pharma — a stock I bought about a month ago in the $6 range is being bought by Cubist Pharma for $13.50 per share — with an additional $2 per share if TSRX “meets certain sales targets.” Shares are up 18% after …
U.S. stock futures suggest a flat to slightly higher start for Wall Street; Cubist Pharmaceuticals makes two acquisitions; MasterCard and Comcast highlight the earnings calendar.
Buy-outs are hard to predict in general, and in many ways, holding stock in a company that receives a tender offer ... MSRA has become a hot topic serious issue as of late, so we expect TSRX to be a big runner in the months ahead. I …
Alpha Natural Resources ANR, +0.00% meanwhile, saw its stock slide more than 7%. Trius Therapeutics shares TSRX dropped 12% to $6.00. The biotech group released results from a Phase III clinical trial for its antibiotic drug candidate …